George Jones, PharmD, the Defense Health Agency's chief of pharmacy operations, reports his organization is taking action to help protect Tricare beneficiaries against recent aggressive and deceptive marketing practices of some compounding pharmacies. "Compounding pharmacies definitely have a role in medical care, a very important role," Jones says. But a phenomenon that has arisen over the past 6 months involves compounding pharmacies "that are charging unsupportable costs for some of these products, and expanding into areas where there is not good evidence to support the products' safety," he adds. Jones says that on May 1, Tricare began extra screening of compound prescriptions to "look at the ingredients to see if there's evidence of safety, to see if it's something that can be marketed in the United States, to make sure it’s in the best interest of that patient and that it’s cost effective." He notes that very preliminary data for May indicate that this screening is having an effect.